Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
November 12, 2024 07:00 ET
|
Avalo Therapeutics
Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 millionCash runway expected into at least...
Avalo Therapeutics to Present at Upcoming Investor Conferences
November 11, 2024 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation,...
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
November 07, 2024 07:00 ET
|
Avalo Therapeutics
Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position of approximately $82 million as of September...
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
October 08, 2024 07:00 ET
|
Avalo Therapeutics
Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to placeboTopline data expected in 2026 WAYNE,...
Avalo Announces Participation in September Investor Conferences
September 04, 2024 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 12, 2024 07:00 ET
|
Avalo Therapeutics
Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024Appointed Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief...
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
July 16, 2024 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical...
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
July 09, 2024 07:00 ET
|
Avalo Therapeutics
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with...
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
June 24, 2024 16:01 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer. “We are...
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
June 17, 2024 07:30 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...